PCR performance in the SARS-CoV-2 Omicron variant of concern?


Journal

Swiss medical weekly
ISSN: 1424-3997
Titre abrégé: Swiss Med Wkly
Pays: Switzerland
ID NLM: 100970884

Informations de publication

Date de publication:
06 12 2021
Historique:
entrez: 15 12 2021
pubmed: 16 12 2021
medline: 21 12 2021
Statut: epublish

Résumé

The new SARS-CoV-2 Omicron variant (B.1.1.529) has been recently declared a Variant of Concern due to a series of important mutations in the viral spike protein and especially in the receptor-binding domain. While investigations into the spread of this new variant are ongoing, the first cases have been detected in Switzerland. Important questions have been raised: (1) Will the PCR assays commonly used to detect SARS-CoV-2 still work for the Omicron variant? (2) Can specific PCR features, e.g. S-gene dropout, be used to identify potential Omicron samples? In this minireview we provide current knowledge on the Omicron variant and guidance on its PCR validation.

Identifiants

pubmed: 34909869
doi: 10.4414/smw.2021.w30120
pii: Swiss Med Wkly. 2021;151:w30120
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

w30120

Auteurs

César M J A Metzger (CMJA)

Federal Office for Civil Protection, Spiez Laboratory, Spiez, Switzerland.

Reto Lienhard (R)

ADMed Microbiologie, La-Chaux-de-Fonds, Switzerland.
Commission of Clinical Microbiology (CCCM) of the Swiss Society of Microbiology.

Helena M B Seth-Smith (HMB)

Clinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland.
Applied Microbiology Research, Department Biomedicine, University of Basel, Basel, Switzerland.

Tim Roloff (T)

Clinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland.
Applied Microbiology Research, Department Biomedicine, University of Basel, Basel, Switzerland.

Fanny Wegner (F)

Applied Microbiology Research, Department Biomedicine, University of Basel, Basel, Switzerland.

Jonas Sieber (J)

Federal Office for Civil Protection, Spiez Laboratory, Spiez, Switzerland.

Michael Bel (M)

Federal Office of Public Health, Bern, Switzerland.

Gilbert Greub (G)

Commission of Clinical Microbiology (CCCM) of the Swiss Society of Microbiology.
Institute for Medical Microbiology, University Hospital Lausanne, Lausanne, Switzerland.

Adrian Egli (A)

Commission of Clinical Microbiology (CCCM) of the Swiss Society of Microbiology.
Clinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland.
Applied Microbiology Research, Department Biomedicine, University of Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH